Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
Data ReadoutnegativeNegative
AI Analysis
Summary
Ultragenyx's Angelman syndrome drug candidate failed a key study, representing a significant setback for what was expected to be a blockbuster therapy. The company is now planning substantial cost reductions in response to the failure.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Key study failed
Importance:8/10
Sentiment:
-0.90
clinical trial failurecost cutsrare diseasepipeline setback
Related Companies
Read the original article
Published by BioPharma Dive on September 3, 2026 2:53 PM